- Home
- MPB vs PCRX Comparison
MPB vs PCRX Comparison
Compare MPB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PCRX
- Stock Information
- Founded
- MPB 1868
- PCRX 2006
- Country
- MPB United States
- PCRX United States
- Employees
- MPB N/A
- PCRX N/A
- Industry
- MPB Major Banks
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PCRX Health Care
- Exchange
- MPB Nasdaq
- PCRX Nasdaq
- Market Cap
- MPB 525.0M
- PCRX 604.7M
- IPO Year
- MPB N/A
- PCRX 2011
- Fundamental
- Price
- MPB $29.97
- PCRX $24.61
- Analyst Decision
- MPB Buy
- PCRX Buy
- Analyst Count
- MPB 2
- PCRX 10
- Target Price
- MPB $36.00
- PCRX $27.60
- AVG Volume (30 Days)
- MPB 60.1K
- PCRX 644.2K
- Earning Date
- MPB 01-22-2025
- PCRX 02-27-2025
- Dividend Yield
- MPB 2.66%
- PCRX N/A
- EPS Growth
- MPB 14.41
- PCRX N/A
- EPS
- MPB 2.91
- PCRX N/A
- Revenue
- MPB $173,416,000.00
- PCRX $694,957,000.00
- Revenue This Year
- MPB N/A
- PCRX $4.83
- Revenue Next Year
- MPB $19.26
- PCRX $2.16
- P/E Ratio
- MPB $10.34
- PCRX N/A
- Revenue Growth
- MPB 4.93
- PCRX 4.40
- 52 Week Low
- MPB $19.20
- PCRX $11.16
- 52 Week High
- MPB $33.87
- PCRX $34.01
- Technical
- Relative Strength Index (RSI)
- MPB 55.21
- PCRX 75.74
- Support Level
- MPB $28.48
- PCRX $18.18
- Resistance Level
- MPB $30.19
- PCRX $22.36
- Average True Range (ATR)
- MPB 0.63
- PCRX 1.21
- MACD
- MPB 0.30
- PCRX 0.36
- Stochastic Oscillator
- MPB 90.57
- PCRX 98.85
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.